Latest news-English – 【國家衛生研究院】技轉及育成中心

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” (2022/11/18)

技術-EN / 2022 年 11 月 18 日 2022 年 11 月 21 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” Date: 2022.11.18 1. Title: NHRI technology, “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: DBPR901 is a humanized anti-HSP90a IgG1 derived from a murine hybridoma …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR901: a Humanized HSP90a Antibody with Anti-Desmoplasia Potency” (2022/11/18) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR22998: IsoQC inhibitor targeting CD47-SIRPa “Do not eat me” cancer immune checkpoint” (2022/11/18)

技術轉移招商en文章, 技術轉移招商en文章, 技術轉移招商en文章, 最新消息 / 2022 年 11 月 18 日 2022 年 11 月 17 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR22998: IsoQC inhibitor targeting CD47-SIRPa “Do not eat me” cancer immune checkpoint” Date: 2022.11.18 1. Title: NHRI technology, “DBPR22998: IsoQC inhibitor targeting CD47-SIRP “Do not eat me” cancer immune checkpoint” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: DBPR22998 is an …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26)

Latest news-English, Latest news-English, Latest news-English, Latest news-English, Latest news-English, Uncategorized, 技術-EN, 產學研發-EN, 產學研發徵求夥伴en文章 / 2022 年 7 月 26 日 2022 年 7 月 26 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” Date: 2022.7.26 1. Title: NHRI technology, “DBPR807: A CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: DBPR807 is a small molecule CXCR4 antagonist. DBPR807 can significantly suppress tumor growth of hepatocellular carcinoma via reducing angiogenesis, …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03)

技術轉移招商en文章, 產學研發-EN / 2022 年 1 月 3 日 2022 年 1 月 3 日

1. Title: NHRI technology, “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: Amplification or overexpression of MYC oncoproteins, master regulator of cancers, are observed in over 28% common cancer types. The Technology is a novel aurora kinase inhibitor which was …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03) Read More »

建構生醫價值鏈，加速生醫產業發展！專訪國衛院育成中心蔡熙文主任

創新育成, 最新消息, 育成-EN / 2020 年 7 月 16 日 2021 年 8 月 30 日

台灣有超過上百家育成中心，主要提供新創公司和中小企業在發展前期的資源，其中包含了空間、儀器設備、研發技術、資金連結、商務服務、管理諮詢等，以降低其創業初期的成本與風險。多數育成中心設置在大學與政府機構。其中，國家衛生研究院技轉及育成中心專注於生物科技與醫療衛生領域，多年以來更是扮演台灣生醫產業發展的重要推手。